A deficiency in fumarate metabolism could be behind a new mechanism of inflammation mediated by mitochondrial DNA and RNA. Two independent and simultaneous studies described how the accumulation of fumarate in the mitochondria released the genetic material of this organelle through vesicles, activating an inflammatory signaling pathway.
Micurx Pharmaceuticals Inc. has patented peptide-drug conjugates consisting of peptide targeting kidney cells covalently linked to an anti-inflammatory or immunomodulating or nephron-protective drug through a linker reported to be useful for the treatment of acute kidney injury, chronic kidney disease, chronic glomerulonephritis, diabetic nephropathy and systemic lupus erythematosus, among others.
Researchers from South China University of Technology and Chengde Medical University presented the discovery and preclinical evaluation of novel xanthine oxidoreductase (XOR) inhibitors as potential uric acid-lowering agents.
Northwest Agriculture & Forestry University has disclosed short transient receptor potential channel 6 (TRPC6) antagonists reported to be useful for the treatment of cancer, sepsis, arthritis, pulmonary arterial hypertension and renal disorders.
Researchers from Cincinnati Children’s Hospital Medical Center have published data from a study that aimed to investigate the role of interleukin-33 (IL-33) in cardiac remodeling after acute kidney injury (AKI).
SUMOylation is a post-translational modification consisting of the covalent addition of SUMO peptides on a target protein, which can affect various processes such as protein stability, interactions or subcellular localizations. This modification finetunes protein function involved in the cellular response to stress, differentiation and tissue development.
Jiangsu Chia Tai Tianqing Pharmaceutical Group Co. Ltd. and Medshine Discovery Inc. have identified benzoxazinone derivatives acting as mineralocorticoid receptor (MR) antagonists reported to be useful for the treatment of diabetic nephropathy.
Scientists in Edinburgh are planning a clinical trial of licensed drugs in the prevention of chronic kidney disease (CKD) following acute kidney injury (AKI), after uncovering a new mechanism linking the pathology of one with the other. It has only recently been recognized that AKI is linked to CKD and cardiovascular disease, and to date the molecular pathways that control the transition are not well-mapped. As a result, there are no therapies for preventing acute injury progressing to chronic disease.
Medshine Discovery Inc. has disclosed alkyl carboxylic acid compounds acting as soluble guanylate cyclase (sGC) activators reported to be useful for the treatment of chronic kidney disease.
Researchers from Anhui Medical University published data from a study that aimed to assess the antifibrotic effects of the transforming growth factor-β (TGF-β) receptor type I (TGFBR1/ALK5) inhibitor Cpd-0225.
RSS
